Graft vs Host Disease Treatment Market: Global Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Graft vs Host Disease Treatment Market: By Drug Class (Monoclonal Antibodies, Immunosuppressive Drugs, Steroids, TNF Inhibitorso, Tyrosine Kinase Inhibitors Others) Disease Type (Acute Graft vs Host Disease, Chronic Graft vs Host Disease) Route of Administration (Oral, Parenteral) Distribution Channel (Hospital Pharmacies, Retail Pharmacies Online Pharmacies) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Graft vs Host Disease Treatment Market size was valued at USD 2,967.9 million in 2021, growing at a CAGR of 8.1% during the forecast period 2022 to 2028. The global market provides a detailed overview of the market, and that can be segmented by Drug Class, Disease Type, by Route of Administration, and by Distribution Channel. By drug class, the global Graft vs Host Disease Treatment market has been segmented into Monoclonal Antibodies, Immunosuppressive Drugs, Steroids, TNF Inhibitorso, Tyrosine Kinase Inhibitors, Others. The monoclonal antibodies segment is likely to be the largest and fastest-growing segment in terms of drug class. Based on Disease Type, the global Graft vs Host Disease Treatment market is segmented into Acute Graft vs Host Disease, Chronic Graft vs Host Disease. Among these, the Acute Graft vs Host Disease segment is expected to have the fastest-growing segment during the forecast period 2022-2028. Based on route of administration, the global Graft vs Host Disease Treatment market is segmented into Oral, Parenteral. The oral segment accounts for the largest share in 2021. Based on the distribution channel, the segment has been segregated into Hospital Pharmacies, Retail Pharmacies Online Pharmacies. The hospital pharmacies segment is expected to dominate other segments in the global market. The retail pharmacies segment is expected to witness the highest CAGR during the forecast period according to precision business insights.

Key Development:

In Sept 2021, Ruxolitinib has been approved by the US Food and Drug Administration (FDA) for the treatment of chronic Graft-versus-Host disease in patients 12 years of age and older who have failed any two conventional therapies.

In May 2022, Jakavi  ruxolitinib) from Novartis has been given European Commission (EC) approval for the treatment of patients with acute or chronic GvHD who have had a poor response to corticosteroids or other systemic treatments and are 12 years of age or older.

Graft vs Host Disease Treatment Market

MARKET SUMMARY
-
8.1% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 8.1%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Graft vs Host Disease Treatment Market

  • The report on the global graft vs host disease treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of additive, source, application, and geography.
  • graft vs host disease treatment market report gives a comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and the Middle East, and Africa.
Key Players
  • Hoffmann-La Roche Ltd.
  • AbbVie, Inc.
  • Bristol-Myers Squibb
  • Pfizer, Inc.
  • Baxter International plc
  • Novartis AG
Graft vs Host Disease Treatment Market Dynamics

Growing Number of Pipeline Drugs and Increasing Rate of Bone Marrow or Hematopoietic Stem Cell Treatment can drive the global Graft vs Host Disease Treatment market growth over the forecast years.


North-America Got Significant Share

Graft vs Host Disease Treatment Market

By region, North America is expected to witness the highest market share during the forecast period due to a good healthcare system, expanding research and development, as well as an increase in the number of transplantation procedures in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Graft vs Host Disease Treatment market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The global Graft vs Host Disease Treatment market size is valued at USD 2,967.9 million in 2021 and is expected to grow at a prominent growth rate during the forecast period 2022 to 2028.

High treatment costs and a lack of awareness and information about the chemotherapeutic management of graft versus host disease may limit market expansion.

The major market players are Pfizer Inc., Novartis, Abbvie Inc., Sanofi (Kadmon Pharmaceuticals), Sanofi (Genzyme), Incyte Corporation, Bristol Myers Squibb Company, Genentech Inc., Astellas Pharma US Inc., and others.


Report

Table Of Content

1. Executive Summary
2. Global Graft vs Host Disease Treatment Market Introduction
2.1. Global Graft vs Host Disease Treatment Market – Taxonomy
2.2. Global Graft vs Host Disease Treatment Market –Definitions
2.2.1. By Drug Class
2.2.2. By Disease Type
2.2.3. By Route of Administration
2.2.4. By Distribution Channel
2.2.5. By Region
3. Global Graft vs Host Disease Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Graft vs Host Disease Treatment Market Dynamic Factors – Impact Analysis
3.6. Global Graft vs Host Disease Treatment Market – Competition Landscape
4. Global Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028
4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Graft vs Host Disease Treatment Market, By Drug Class, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1. Monoclonal Antibodies
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Immunosuppressive Drugs
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Steroids
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. TNF Inhibitors
5.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Tyrosine Kinase Inhibitors
5.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Graft vs Host Disease Treatment Market, By Disease Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1. Acute Graft vs Host Disease
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Chronic Graft vs Host Disease
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Graft vs Host Disease Treatment Market, By Route of Administration, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1. Oral
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Parenteral
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. Global Graft vs Host Disease Treatment Market, By Distribution Channel, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. Global Graft vs Host Disease Treatment Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.1. North America
9.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Region, 2022-2028
10. North America Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
10.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Monoclonal Antibodies
10.1.2. Immunosuppressive Drugs
10.1.3. Steroids
10.1.4. TNF Inhibitors
10.1.5. Tyrosine Kinase Inhibitors
10.1.6. Others
10.2. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Acute Graft vs Host Disease
10.2.2. Chronic Graft vs Host Disease
10.3. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Oral
10.3.2. Parenteral
10.4. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. USA
10.5.2. Canada
10.6. North America Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2022-2028
10.7. North America Graft vs Host Disease Treatment Market Dynamics – Trends
11. Europe Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
11.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Monoclonal Antibodies
11.1.2. Immunosuppressive Drugs
11.1.3. Steroids
11.1.4. TNF Inhibitors
11.1.5. Tyrosine Kinase Inhibitors
11.1.6. Others
11.2. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Acute Graft vs Host Disease
11.2.2. Chronic Graft vs Host Disease
11.3. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oral
11.3.2. Parenteral
11.4. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Rest of Europe
11.6. Europe Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2022-2028
11.7. Europe Graft vs Host Disease Treatment Market Dynamics – Trends
12. Asia-Pacific Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
12.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Monoclonal Antibodies
12.1.2. Immunosuppressive Drugs
12.1.3. Steroids
12.1.4. TNF Inhibitors
12.1.5. Tyrosine Kinase Inhibitors
12.1.6. Others
12.2. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Acute Graft vs Host Disease
12.2.2. Chronic Graft vs Host Disease
12.3. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oral
12.3.2. Parenteral
12.4. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2022-2028
12.7. Asia-Pacific Graft vs Host Disease Treatment Market Dynamics – Trends
13. Latin America Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
13.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Monoclonal Antibodies
13.1.2. Immunosuppressive Drugs
13.1.3. Steroids
13.1.4. TNF Inhibitors
13.1.5. Tyrosine Kinase Inhibitors
13.1.6. Others
13.2. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Acute Graft vs Host Disease
13.2.2. Chronic Graft vs Host Disease
13.3. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oral
13.3.2. Parenteral
13.4. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2022-2028
13.7. Latin America Graft vs Host Disease Treatment Market Dynamics – Trends
14. Middle East and Africa Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
14.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Monoclonal Antibodies
14.1.2. Immunosuppressive Drugs
14.1.3. Steroids
14.1.4. TNF Inhibitors
14.1.5. Tyrosine Kinase Inhibitors
14.1.6. Others
14.2. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.2.1. Acute Graft vs Host Disease
14.2.2. Chronic Graft vs Host Disease
14.3. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oral
14.3.2. Parenteral
14.4. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. South Africa
14.5.3. Rest of MEA
14.6. MEA Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2022-2028
14.7. MEA Graft vs Host Disease Treatment Market Dynamics – Trends
15. Competition Landscape
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Key Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. F. Hoffmann-La Roche Ltd.
15.2.2. AbbVie, Inc.
15.2.3. Bristol-Myers Squibb
15.2.4. Pfizer, Inc.
15.2.5. Baxter International plc
15.2.6. Novartis AG
15.2.7. Eli Lilly and Co.
15.2.8. Shire plc
15.2.9. Alleran plc
15.2.10. Caladrius
15.2.11. Eisai
15.2.12. Anterogen
16. Research Methodology
17. Key Assumptions and Acronyms

Report

Company Profile

  • Hoffmann-La Roche Ltd.
  • AbbVie, Inc.
  • Bristol-Myers Squibb
  • Pfizer, Inc.
  • Baxter International plc
  • Novartis AG
  • Eli Lilly and Co.
  • Shire plc
  • Alleran plc
  • Caladrius
  • Eisai
  • Anterogen

Description

Graft vs Host Disease Treatment Market size was valued at USD 2,967.9 million in 2021, growing at a CAGR of 8.1% during the forecast period 2022 to 2028. The global market provides a detailed overview of the market, and that can be segmented by Drug Class, Disease Type, by Route of Administration, and by Distribution Channel. By drug class, the global Graft vs Host Disease Treatment market has been segmented into Monoclonal Antibodies, Immunosuppressive Drugs, Steroids, TNF Inhibitorso, Tyrosine Kinase Inhibitors, Others. The monoclonal antibodies segment is likely to be the largest and fastest-growing segment in terms of drug class. Based on Disease Type, the global Graft vs Host Disease Treatment market is segmented into Acute Graft vs Host Disease, Chronic Graft vs Host Disease. Among these, the Acute Graft vs Host Disease segment is expected to have the fastest-growing segment during the forecast period 2022-2028. Based on route of administration, the global Graft vs Host Disease Treatment market is segmented into Oral, Parenteral. The oral segment accounts for the largest share in 2021. Based on the distribution channel, the segment has been segregated into Hospital Pharmacies, Retail Pharmacies Online Pharmacies. The hospital pharmacies segment is expected to dominate other segments in the global market. The retail pharmacies segment is expected to witness the highest CAGR during the forecast period according to precision business insights.

Key Development:

In Sept 2021, Ruxolitinib has been approved by the US Food and Drug Administration (FDA) for the treatment of chronic Graft-versus-Host disease in patients 12 years of age and older who have failed any two conventional therapies.

In May 2022, Jakavi  ruxolitinib) from Novartis has been given European Commission (EC) approval for the treatment of patients with acute or chronic GvHD who have had a poor response to corticosteroids or other systemic treatments and are 12 years of age or older.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX